Normalized Income after Taxes: A company's after tax profit or loss smoothed out by elimination of all non-recurring items.
Lakewood-Amedex Biotherapeutics Inc. (LABT) had Normalized Income after Taxes of -0.92M for the most recently reported fiscal quarter, ending 2026-03-31.
| Income Statement Financials | |
-- |
|
-1.42M |
|
-- |
|
-- |
|
0.89M |
|
-0.89M |
|
-0.04M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
-0.92M |
|
|
Normalized Income after Taxes |
-0.92M |
-0.89M |
|
-0.86M |
|
0.70M |
|
0.70M |
|
-2.00 |
|
-2.00 |
|
| Balance Sheet Financials | |
0.05M |
|
0.01M |
|
0.15M |
|
0.20M |
|
3.03M |
|
-- |
|
0.01M |
|
3.04M |
|
-2.84M |
|
-2.84M |
|
-2.84M |
|
0.70M |
|
| Cash Flow Statement Financials | |
-0.35M |
|
0.00M |
|
0.12M |
|
0.24M |
|
0.01M |
|
-0.22M |
|
0.05M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
0.02 |
|
-- |
|
-- |
|
-- |
|
-0.57 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-0.35M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
32.46% |
|
32.49% |
|
-470.24% |
|
32.49% |
|
-4.06 |
|
-0.50 |
|
-0.50 |
|